Opendata, web and dolomites

anTBiotic SIGNED

AnTBiotic – progressing TB drug candidates to clinical proof of concept

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "anTBiotic" data sheet

The following table provides information about the project.

Coordinator
GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL 

Organization address
address: C/ SEVERO OCHOA NUMERO 2 PARQUE TECNOLOGICO DE MADRID
city: TRES CANTOS
postcode: 28760
website: www.gsk.es/html/investigacion/espana.html

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.antbiotic.eu
 Total cost 5˙819˙416 €
 EC max contribution 5˙819˙416 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2016-RTD
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL ES (TRES CANTOS) coordinator 1˙923˙768.00
2    TASK FOUNDATION NPC ZA (CAPE TOWN) participant 1˙873˙804.00
3    FORSCHUNGSZENTRUM BORSTEL DE (BORSTEL) participant 1˙242˙417.00
4    UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET NO (TROMSO) participant 644˙072.00
5    UNIVERSITY OF CAPE TOWN ZA (RONDEBOSCH) participant 135˙353.00

Map

 Project objective

Tuberculosis (TB) today rivals HIV/AIDS as the leading cause of death from infectious diseases. The number of TB patients has never been higher and the growing proportion of drug-resistant TB is threatening control strategies both in the developing and developed world, Eastern Europe being a particularly worrying point in case. The anTBiotic consortium aims to fuel the long-term TB clinical pipeline while immediately offering new options to clinicians when confronted with multidrug-resistant (MDR)-TB. More specifically, the proposed studies aim to:

a) Establish the proof of concept of anti-TB efficacy in humans of a pioneering, first-in-class, low-dose GSK oxaborole clinical drug candidate; b) Identify a combination of β-lactam antibiotics suitable for the treatment of MDR TB orally or as a once daily intravenous or intramuscular application and c) Incorporate the best β-lactam combination into an explorative salvage regimen for untreatable patients with extensively drug-resistant TB

The anti-TB activity in humans will be established in a two-week EBA clinical studies that combine established (CFU, TTP) and new clinical markers (biomarkers, PET/CT). These datasets will help ascertain anti-TB efficacy in humans and generate confidence on their validity in longer-term drug combination trials. A variety of modelling approaches to predict optimal dosing will be used. Finally, we intend to use at least one of these novel anti-TB entities as part of a pioneering, non-controlled clinical trial in highly drug resistant subjects in Europe and South Africa. This final clinical intervention will hopefully be of immediate benefit to drug-resistant patients in the EU and elsewhere in addition to generating a strong precedent for further adoption worldwide.

 Deliverables

List of deliverables.
Project Website Websites, patent fillings, videos etc. 2019-06-14 12:42:31
Dissemination Plan Documents, reports 2019-06-14 12:42:31

Take a look to the deliverables list in detail:  detailed list of anTBiotic deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Fabrizio Clarelli, Jingyi Liang, Antal Martinecz, Ines Heiland, Pia Abel zur Wiesch
Multi-scale modeling of drug binding kinetics to predict drug efficacy
published pages: , ISSN: 1420-682X, DOI: 10.1007/s00018-019-03376-y
Cellular and Molecular Life Sciences 2020-02-13
2020 Veronique R. de Jager, Naadira Vanker, Lize van der Merwe, Elana van Brakel, Morris Muliaditan, Andreas H Diacon
Optimising β-lactams Against Tuberculosis
published pages: , ISSN: 1073-449X, DOI: 10.1164/rccm.201911-2149le
American Journal of Respiratory and Critical Care Medicine 2020-02-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ANTBIOTIC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ANTBIOTIC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More